|0.02752 -0.003 (-8.27%)||12-08 15:51|
|Targets||6-month :||0.18||1-year :||0.29|
|Resists||First :||0.16||Second :||0.25|
|Supports||First :||0.02||Second :||0.01|
|MAs||MA(5) :||0.02||MA(20) :||0.07|
|MA(100) :||0.33||MA(250) :||1.19|
|MACD||MACD :||-0.1||Signal :||-0.1|
|%K %D||K(14,3) :||5.8||D(3) :||4.1|
|52-week||High :||6.88||Low :||0.02|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BXRX ] has closed above bottom band by 24.5%. Bollinger Bands are 59.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
|If tomorrow:||Open lower||Open higher|
|High:||0.03 - 0.03||0.03 - 0.03|
|Low:||0.02 - 0.02||0.02 - 0.02|
|Close:||0.03 - 0.03||0.03 - 0.03|
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.
Thu, 28 Sep 2023
Why Is Baudax Bio (BXRX) Stock Up 75% Today? - InvestorPlace
Tue, 04 Jul 2023
Baudax Bio Acquires TeraImmune - FinSMEs
Fri, 30 Jun 2023
Baudax Bio Acquires TeraImmune - citybiz
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||0 (M)|
|Shares Float||44 (M)|
|Held by Insiders||4.357e+007 (%)|
|Held by Institutions||11.6 (%)|
|Shares Short||36 (K)|
|Shares Short P.Month||0 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||0|
|Profit Margin||0 %|
|Operating Margin||-2 %|
|Return on Assets (ttm)||759.8 %|
|Return on Equity (ttm)||-115 %|
|Qtrly Rev. Growth||1.27e+006 %|
|Gross Profit (p.s.)||0|
|Sales Per Share||0|
|Qtrly Earnings Growth||-94.2 %|
|Operating Cash Flow||0 (M)|
|Levered Free Cash Flow||-14 (M)|
|Price to Book value||0|
|Price to Sales||0|
|Price to Cash Flow||-0.07|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|